These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 479345)

  • 1. The potential for an androgen male contraceptive.
    Cunningham GR; Silverman VE; Thornby J; Kohler PO
    J Clin Endocrinol Metab; 1979 Oct; 49(4):520-6. PubMed ID: 479345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate.
    Tom L; Bhasin S; Salameh W; Steiner B; Peterson M; Sokol RZ; Rivier J; Vale W; Swerdloff RS
    J Clin Endocrinol Metab; 1992 Aug; 75(2):476-83. PubMed ID: 1639948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations.
    Wallace EM; Gow SM; Wu FC
    J Clin Endocrinol Metab; 1993 Jul; 77(1):290-3. PubMed ID: 8325955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production.
    Matsumoto AM
    J Clin Endocrinol Metab; 1990 Jan; 70(1):282-7. PubMed ID: 2104626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. III. Higher 5 alpha-reductase activity in oligozoospermic men administered supraphysiological doses of testosterone.
    Anderson RA; Wallace AM; Wu FC
    J Clin Endocrinol Metab; 1996 Mar; 81(3):902-8. PubMed ID: 8772548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach.
    Bebb RA; Anawalt BD; Christensen RB; Paulsen CA; Bremner WJ; Matsumoto AM
    J Clin Endocrinol Metab; 1996 Feb; 81(2):757-62. PubMed ID: 8636300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
    Behre HM; Nashan D; Hubert W; Nieschlag E
    J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
    Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low dose of cyproterone acetate and testosterone enanthate for contraception in men.
    Meriggiola MC; Bremner WJ; Costantino A; Di Cintio G; Flamigni C
    Hum Reprod; 1998 May; 13(5):1225-9. PubMed ID: 9647551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of human spermatogenesis by testosterone implants.
    Handelsman DJ; Conway AJ; Boylan LM
    J Clin Endocrinol Metab; 1992 Nov; 75(5):1326-32. PubMed ID: 1430094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido.
    Pavlou SN; Brewer K; Farley MG; Lindner J; Bastias MC; Rogers BJ; Swift LL; Rivier JE; Vale WW; Conn PM
    J Clin Endocrinol Metab; 1991 Dec; 73(6):1360-9. PubMed ID: 1955518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of spermatogenesis by testosterone enanthate in Thai men.
    Aribarg A; Sukcharoen N; Chanprasit Y; Ngeamvijawat J; Kriangsinyos R
    J Med Assoc Thai; 1996 Oct; 79(10):624-9. PubMed ID: 8996996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens.
    Bagatell CJ; Matsumoto AM; Christensen RB; Rivier JE; Bremner WJ
    J Clin Endocrinol Metab; 1993 Aug; 77(2):427-32. PubMed ID: 8345047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive.
    Meriggiola MC; Bremner WJ; Paulsen CA; Valdiserri A; Incorvaia L; Motta R; Pavani A; Capelli M; Flamigni C
    J Clin Endocrinol Metab; 1996 Aug; 81(8):3018-23. PubMed ID: 8768868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of long-term treatment with levo-norgestrel and testosterone enanthate in normal men.
    Foegh M; Nicol K; Petersen IB; Schou G
    Contraception; 1980 Jun; 21(6):631-40. PubMed ID: 6775869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. II. Pharmacokinetics and pharmacodynamics of once weekly administration of testosterone enanthate.
    Anderson RA; Wu FC
    J Clin Endocrinol Metab; 1996 Mar; 81(3):896-901. PubMed ID: 8772547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone.
    Swerdloff RS; Bagatell CJ; Wang C; Anawalt BD; Berman N; Steiner B; Bremner WJ
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3527-33. PubMed ID: 9768659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversible azoospermia induced by an androgen-progestin combination regimen in Indonesian men.
    Pangkahila W
    Int J Androl; 1991 Aug; 14(4):248-56. PubMed ID: 1831798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daily testosterone and gonadotropin levels are similar in azoospermic and nonazoospermic normal men administered weekly testosterone: implications for male contraceptive development.
    Amory JK; Anawalt BD; Bremner WJ; Matsumoto AM
    J Androl; 2001; 22(6):1053-60. PubMed ID: 11700852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral progestogen combined with testosterone as a potential male contraceptive: additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary-testicular axis, and lipid metabolism.
    Wu FC; Balasubramanian R; Mulders TM; Coelingh-Bennink HJ
    J Clin Endocrinol Metab; 1999 Jan; 84(1):112-22. PubMed ID: 9920070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.